OBJECTIVE
To evaluate the real-world impact of liposomal bupivacaine (LB)
on opioid use and healthcare utilization for up to 12 months
following total hip arthroplasty (THA)
CONCLUSIONS
Medicare fee-for-service beneficiaries receiving LB for
outpatient THA experienced lower opioid use and had
fewer opioid-related adverse events (ORAEs) and lower
total medical costs driven by fewer inpatient readmissions
These data support the clinical and economic value of LB
for patients undergoing THA in outpatient care settings